[Form 4] Spyre Therapeutics, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan exercised options to acquire 8,334 shares of common stock at an exercise price of $27.46 per share, then sold the same 8,334 shares in open-market transactions.
The sales occurred on July 1, 2026 at weighted average prices of $87.52 and $88.34 per share, with individual trades ranging from $87.03 to $88.95, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. Following these transactions, Sloan reported no directly held common shares and 305,000 stock options outstanding, part of an option grant for 400,000 shares scheduled to fully vest over four years and expiring on October 1, 2034.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 8,334 shares ($730,896)
Net Sell
4 txns
Insider
Sloan Sheldon
Role
Chief Medical Officer
Sold
8,334 shs ($731K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 8,334 | $0.00 | -- |
| Exercise | Common Stock | 8,334 | $27.46 | $229K |
| Sale | Common Stock | 6,500 | $87.52 | $569K |
| Sale | Common Stock | 1,834 | $88.34 | $162K |
Holdings After Transaction:
Stock Option (Right to Buy) — 305,000 shares (Direct, null);
Common Stock — 8,334 shares (Direct, null)
Footnotes (1)
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Key Figures
Shares sold: 8,334 shares
Sale price (weighted average): $87.52/share and $88.34/share
Sale price ranges: $87.03–$87.99 and $88.03–$88.95
+5 more
8 metrics
Shares sold
8,334 shares
Common stock sold in open-market transactions on July 1, 2026
Sale price (weighted average)
$87.52/share and $88.34/share
Two reported weighted average sale prices for common stock
Sale price ranges
$87.03–$87.99 and $88.03–$88.95
Price ranges for multiple sale transactions
Option exercise price
$27.46/share
Exercise price for 8,334 options converted into common stock
Remaining stock options
305,000 options
Options to purchase common stock held after transactions
Total option grant size
400,000 shares
Underlying shares for the CMO’s stock option award
Option expiration date
October 1, 2034
Expiration for the reported stock option grant
10b5-1 plan adoption date
June 20, 2025
Date the pre-arranged trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vested and became exercisable, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... represents the right to purchase 400,000 shares of the Issuer's common stock..."
vested and became exercisable financial
"one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting..."
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
